These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 12856386)

  • 21. Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide.
    Mousa SA; Johansen K
    Int Angiol; 2005 Mar; 24(1):40-2. PubMed ID: 15876997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor.
    Mousa SA; Mohamed S
    Thromb Haemost; 2004 Sep; 92(3):627-33. PubMed ID: 15351861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
    Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
    Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
    Alban S; Gastpar R
    Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.
    Bendz B; Hansen JB; Andersen TO; Ostergaard P; Sandset PM
    Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations.
    Ostergaard P; Nordfang O; Petersen LC; Valentin S; Kristensen H
    Haemostasis; 1993 Mar; 23 Suppl 1():107-11. PubMed ID: 8388348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of low molecular weight heparins in animal models.
    Fareed J; Fu K; Yang LH; Hoppensteadt DA
    Semin Thromb Hemost; 1999; 25 Suppl 3():51-5. PubMed ID: 10549716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentiation of the low-molecular-weight heparins.
    Racine E
    Pharmacotherapy; 2001 Jun; 21(6 Pt 2):62S-70S; discussion 71S-72S. PubMed ID: 11401195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparin/low molecular weight heparin and tissue factor pathway inhibitor.
    Abildgaard U
    Haemostasis; 1993 Mar; 23 Suppl 1():103-6. PubMed ID: 8388347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bemiparin: pharmacological profile.
    Sánchez-Ferrer CF
    Drugs; 2010 Dec; 70 Suppl 2():19-23. PubMed ID: 21162606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of tissue factor pathway inhibitor in tumor growth and metastasis.
    Amirkhosravi A; Meyer T; Amaya M; Davila M; Mousa SA; Robson T; Francis JL
    Semin Thromb Hemost; 2007 Oct; 33(7):643-52. PubMed ID: 18000790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low molecular weight heparins: are they different?
    Fareed J; Hoppensteadt D; Jeske W; Clarizio R; Walenga JM
    Can J Cardiol; 1998 Aug; 14 Suppl E():28E-34E. PubMed ID: 9779031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heparin and low-molecular weight heparins in thrombosis and beyond.
    Mousa SA
    Methods Mol Biol; 2010; 663():109-32. PubMed ID: 20617415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?
    Johansen KB; Balchen T
    Exp Hematol Oncol; 2013; 2():21. PubMed ID: 23927414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are low molecular weight heparins the same?
    Mousa SA
    Methods Mol Med; 2004; 93():49-59. PubMed ID: 14733327
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects.
    Mousa SA; Bozarth J; Barrett JS
    J Clin Pharmacol; 2003 Jul; 43(7):727-34. PubMed ID: 12856386
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.